28 related articles for article (PubMed ID: 12532336)
1. Regulation of androgen and vitamin d receptors by 1,25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells.
Leman ES; DeMiguel F; Gao AC; Getzenberg RH
J Urol; 2003 Jul; 170(1):235-40. PubMed ID: 12796696
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D and androgen regulation of prostatic growth.
Leman ES; Arlotti JA; Dhir R; Getzenberg RH
J Cell Biochem; 2003 Sep; 90(1):138-47. PubMed ID: 12938163
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo effects of vitamin D (calcitriol) administration on the normal neonatal and prepubertal prostate.
Konety BR; Leman E; Vietmeier B; Arlotti J; Dhir R; Getzenberg RH
J Urol; 2000 Nov; 164(5):1812-8. PubMed ID: 11025775
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
5. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
Swamy N; Persons KS; Chen TC; Ray R
J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
[TBL] [Abstract][Full Text] [Related]
6. Effects of 1,25-dihydroxyvitamin D3 on the distribution of androgen and vitamin D receptors in human prostate neonatal epithelial cells.
Leman ES; Getzenberg RH
J Cell Biochem; 2003 Feb; 88(3):609-22. PubMed ID: 12532336
[TBL] [Abstract][Full Text] [Related]
7. 1alpha,25-dihydroxyvitamin D3 inducible transcription factor and its role in the vitamin D action.
Nezbedova P; Brtko J
Endocr Regul; 2004 Mar; 38(1):29-38. PubMed ID: 15147236
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic corruption of VDR signalling in malignancy.
Abedin SA; Banwell CM; Colston KW; Carlberg C; Campbell MJ
Anticancer Res; 2006; 26(4A):2557-66. PubMed ID: 16886664
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia.
Adorini L; Penna G; Fibbi B; Maggi M
Ann N Y Acad Sci; 2010 Apr; 1193():146-52. PubMed ID: 20398021
[TBL] [Abstract][Full Text] [Related]
10. Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism.
Price DK; Franks ME; Figg WD
J Urol; 2004 Feb; 171(2 Pt 2):S45-9; discussion S49. PubMed ID: 14713753
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D in Prostate Cancer.
Ahn J; Park S; Zuniga B; Bera A; Song CS; Chatterjee B
Vitam Horm; 2016; 100():321-55. PubMed ID: 26827958
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
